Vedolizumab and Vedolizumab Antibody
Synonyms |
|
||||||||||||
Cerner Name |
|||||||||||||
Clinical Info |
Provides serum concentrations of vedolizumab and anti-vedolizumab antibodies in order to optimize treatment and facilitate clinical decision-making. |
||||||||||||
Specimen Sources |
Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous |
||||||||||||
Specimen Types |
Blood |
||||||||||||
Specimen Volume |
2 mL serum (1 mL min) |
||||||||||||
Container |
Gold Top Tube |
||||||||||||
Collection Instructions |
Container/Tube: Gold Top Tube or Red Top Tube |
||||||||||||
Transport Instructions |
|||||||||||||
Specimen Stability |
14 Days Room Temperature |
||||||||||||
Methodology |
Electrochemiluminescence Immunoassay (ECLIA) |
||||||||||||
Days Performed |
TAT: 9-16 Days |
||||||||||||
Performing Laboratories |
|
||||||||||||
CPT |
80280,82397 |
||||||||||||
PDM |
1759547 |
||||||||||||
Results |
|
||||||||||||
Result InterpretationSee Report In the absence of anti-vedolizumab antibodies, the vedolizumab drug level reflects the total vedolizumab concentration. In the presence of anti-vedolizumab antibodies, the vedolizumab concentration reflects the antibody-unbound fraction of vedolizumab. |
|||||||||||||
Forms |
|||||||||||||

